IDEAYA Biosciences Raises $150M in Stock Offering After Promising Cancer Data

Ideaya Biosciences has announced interim results from its Phase II clinical trial investigating a combination of darovasertib and crizotinib to treat metastatic uveal melanoma (MUM). The biotech is also moving ahead with an offering of up to $150 million of shares of its common stock in a public offering. In other news, the FDA granted accelerated approval to Biogen’s treatment for a rare type of amyotrophic lateral sclerosis, or ALS, giving a small subset of patients a new and much-needed treatment option.